A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection

The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.

For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Genotype 3 HCV
• HCV RNA ≥10000 IU (International Unit)/mL
• Compensated Liver Cirrhosis
• BMI 18-40 kg/m2
• Previously treated for HCV or never treated for HCV

Exclusion Criteria:

• Infection with HCV other than Genotype 3. Mixed infection of any genotype
• Evidence of decompensated liver disease
• Previous exposure to NS5A inhibitors

Other protocol defined inclusion/exclusion criteria could apply